Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants

• Published in: International journal of cancer Vol. 80; no. 1; pp. 54 - 59
• Main Authors: KANEKO, Y, KOBAYASHI, H, MASEKI, N, NAKAGAWARA, A, SAKURAI, M
• Format: Journal Article
• Language: English
• Published: New York, NY Wiley-Liss 05-01-1999
• Subjects: Aneuploidy; Biological and medical sciences; Brain Neoplasms - diagnosis; Brain Neoplasms - genetics; Brain Neoplasms - mortality; Brain Neoplasms - surgery; Catecholamines - urine; Child; Child, Preschool; Chromosome Deletion; Chromosome Mapping; Chromosomes, Human, Pair 1; Confidence Intervals; Disease-Free Survival; Gene Amplification; Genes, myc; Humans; Infant; Japan; Loss of Heterozygosity; Mass Screening - methods; Medical sciences; Neuroblastoma - diagnosis; Neuroblastoma - genetics; Neuroblastoma - mortality; Neuroblastoma - surgery; Neurology; Reproducibility of Results; Survival Rate; Trisomy; Tumors of the nervous system. Phacomatoses; Japan; Chromosomal aberration; Human; Nervous system diseases; Late; Infant; Malignant tumor; Neuroblastoma; Medical screening; Abnormal chromosome A1; Cytogenetics; Deletion; Abnormal chromosome; Genetics; Autonomic neuropathy; Child; Public health
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/(SICI)1097-0215(19990105)80:1<54::AID-IJC11>3.0.CO;2-G

The mass screening (MS) of neuroblastoma has been undertaken in Japan by measuring urinary catecholamine metabolites in infants at the age of 6 months. To clarify the biological characteristics of MS-positive (MS+) tumors in infants and MS-negative (MS-)/late-presenting tumors in young children, metaphase cytogenetic and/or interphase 2-color FISH analyses using terminal 1p and pericentromeric 1q probes were performed on 246 (186 MS+ and 60 MS-) patients with neuroblastomas. The 246 tumors were classified into 4 groups on the basis of the constitution of chromosome 1; 22 tumors had disomy 1 with no 1p deletion (Dis1Norm1p); 41 tumors had disomy 1 or tetrasomy 1, all with the 1p deletion (Dis1Del1p); 164 tumors had trisomy 1, pentasomy 1, or a mixed population of cells with trisomy 1 and cells with tetrasomy 1, none with 1p deletion (Tris1Norm1p); 19 tumors with the same copy numbers of chromosome 1 as the Tris1Norm1p group, had 1p deletion (Tris1Del1p). mycn amplification was absent in the Dis1Norm1p and Tris1Del1p groups, frequent in the Dis1Del1p group (24/41), and rare in the Tris1Norm1p group (3/164) (p < 0.0001). Event-free survival at 5 years was lowest [19.5%; 95% confidence interval (CI), 5.1-33.9] in the Dis1Del1p group, highest in the Tris1Norm1p (96.3%; 95% CI, 93.5-99.2) and Tris1Del1p (94.7%; 95% CI, 84.7-104.8) groups, and intermediate but varied (54.5%; 95% CI, 33.7-75.4) in the Dis1Norm1p group (p < 0.0001). Of the MS+ tumors, 90% were Tris1Norm1p or Tris1Del1p, and 55% of the MS- tumors were Dis1Del1p. The finding that the Dis1Del1p tumors were frequent in MS- but not in MS+ tumors suggests the limited efficacy of the MS program into reducing mortality from neuroblastoma.